Research programme: cancer therapeutics - Netris Pharma

Drug Profile

Research programme: cancer therapeutics - Netris Pharma

Alternative Names: Anti-SEMA3E monoclonal antibody - Netris Pharma; Anti-semaphorin 3E monoclonal antibody - Netris Pharma; Anti-TrkC monoclonal antibody - Netris Pharma; Anti-tropomyosin receptor kinase C monoclonal antibody - Netris Pharma; SEMA 3E - Netris Pharma

Latest Information Update: 14 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Netris Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Semaphorin modulators; TrkC receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Dec 2016 Preclinical trials in Cancer in France (Parenteral) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top